Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Recurrence risk prediction in resected stage I-III melanoma utilizing circulating tumor DNA.

BMC cancer - 24 Nov 2025

Zhao Mengke, Zhao Lianjun, Yang Yueling, Wang Fufeng, Yin Jiani, Wu Xiaoying, Ren Yu, Su Xinyu, Wu Yirong, Li Luqiao, Huang Rong, Zheng Kelin, Wang JiaYu, Zou Zhengyun

Abstract excerpt

BACKGROUND: Adjuvant therapies are now considered standard care for high-risk melanoma patients. It is urgent to identify reliable biomarkers to select patients at high risk of relapse, who will derive more benefit from adjuvant therapy. METHODS: Targeted next-generation sequencing using a 437 cancer-related gene panel was performed on primary tumor samples from 55 patients in stage I-III melanoma and...

Read the complete abstract on PubMed

Topics

Humans
Melanoma
Male
Female
Middle Aged
Circulating Tumor DNA

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Neoplasm Recurrence, Local

Aged

Adult

Biomarkers, Tumor

Neoplasm Staging

High-Throughput Nucleotide Sequencing

Aged, 80 and over

Skin Neoplasms

Prognosis

Disease-Free Survival

Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 41286758
DOI: 10.1186/s12885-025-15093-w
PMCID: PMC12641966

Genes

BRAF
KIT
NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Recurrence risk prediction in resected stage I-III melanoma utilizing circulating tumor DNA.PMID 41286758Read ↗

Sensitivity and prognostic significance of circulating tumor DNA (ctDNA) in stage I to III malignant melanoma.Semantic proximity Read ↗

Feasibility of personalized circulating tumor DNA detection in stage II and III melanoma.Semantic proximity Read ↗

Circulating Tumor DNA: A Promising Biomarker for Predicting Recurrence in Patients with BRAF-Negative Melanoma.Semantic proximity Read ↗

New Perspectives and Open Issues in the Adjuvant and Neoadjuvant Treatment of MelanomaSemantic proximity Read ↗

Monitoring circulating tumor DNA liquid biopsy in stage III BRAF-mutant melanoma patients undergoing adjuvant treatment.Semantic proximity Read ↗

Personalized follow-up of circulating DNA in resected stage III/IV melanoma: PERCIMEL multicentric prospective study protocol.Semantic proximity Read ↗

In-depth assessment of BRAF, NRAS, KRAS, EGFR, and PIK3CA mutations on cell-free DNA in the blood of melanoma patients receiving immune checkpoint inhibition.Semantic proximity Read ↗

Melanoma risk loci as determinants of melanoma recurrence and survival.Semantic proximity Read ↗

Clinical Impact of Immune Checkpoint Inhibitor (ICI) Response, DNA Damage Repair (DDR) Gene Mutations and Immune-Cell Infiltration in Metastatic Melanoma Subtypes.Semantic proximity Read ↗

TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy.Semantic proximity Read ↗

Circulating Tumor DNA (ctDNA) Clearance After Immune Checkpoint Inhibition (ICI) with Radiotherapy (RT) as a Prognostic Biomarker for Advanced MelanomaSemantic proximity Read ↗

Development and validation of postoperative circulating tumor DNA combined with clinicopathological risk factors for recurrence prediction in patients with stages I-III colorectal cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.